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ABSTRACT
Ovarian cancer is an aggressive and lethal cancer usually treated by cytoreductive 
surgery followed by chemotherapy. Unfortunately, after an initial response, many 
patients relapse owing mainly to the development of resistance against the standard 
chemotherapy regime, carboplatin/paclitaxel, which is also affected by heavy side 
effects. In view to addressing such issues here, an association of liposomal cisplatin 
with 6-amino nicotinamide is investigated. It is known that resistant cells increase their 
demand for glucose, which is partially redirected toward the pentose phosphate pathway 
(PPP). Interestingly, we have found that also a cisplatin-resistant subclone of the 
ovarian cancer cells IGROV1 switch their metabolism toward the glycolytic pathway and 
rely on PPP to elude cisplatin cytotoxicity. The drug 6-amino nicotinamide, an 
inhibitor of the enzyme glucose-6-phosphate dehydrogenase (the rate-limiting step 
of the PPP) can restore the sensitivity of resistant cells to cisplatin. Then, to reduce 
the toxicity of cisplatin and prolong its action, a lyophilized stealth liposomal formulation 
of cisplatin was developed. The combination treatment of liposomal cisplatin and 
6-amino nicotinamide showed promising cytotoxic activities in drug-resistant cells and 
a prolonged pharmacokinetics in rats, thus opening the way for a new therapeutic option 
against ovarian cancer.
INTRODUCTION
Ovarian cancer (OC) is one of the most aggressive 
and lethal gynecological cancers with an incidence in 
2012 of about 240,000 women/y and a mortality of 
about 150,000 women/y [1]. Nevertheless, the incidence 
and mortality forecasts of this tumor are expected to 
increase in the next years [1], and the 5-year survival rate 
is approximately 45%. One of the main issues of OC is 
that about 70% of patients are diagnosed with advanced 
disease (FIGO III/IV tumor stages), with several tumor 
nodes present and disseminated in the peritoneal cavity, 
thus impacting the success of treatment [2]. Furthermore, 
ascites can be a reservoir of aggressive cancer cells that 
facilitate the peritoneal dissemination. Consequently, any 
new approach of OC therapy should target various kinds 
of tumoral cells and/or tissues. Currently, standard initial 
management of advanced stages of OC is cytoreductive 
surgery [3], followed by a chemotherapy based on an 
association of carboplatin-paclitaxel [4–6]. Unfortunately, 
although an initial 70-80% response rate, most patients 
relapse due to development of diseases resistant to 
chemotherapy [7]. Carboplatin/paclitaxel therapy is 
limited by the risk of cumulative peripheral neuropathy 
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[8]. Better results have been achieved in clinical trials 
with cisplatin when the doses used are doubled, but this 
approach is impractical due to the associated toxicity with 
a high-dose chemotherapy. In fact, anticancer drugs are 
usually low molecular weight molecules presenting poor 
bioavailability, low water solubility, non-specific body 
distribution and very modest cancer cell selectivity; thus 
they have several systemic toxicities with a consequent 
low patient compliance. It is therefore evident that 
unravelling the mechanisms causing chemoresistance is 
crucial for personalized therapy and the improvement of 
patients’ long-term survival.
In order to develop innovative strategies enabling to 
limit not only the onset of cisplatin-resistance mechanisms 
but also to reduce its dosage in chemotherapy, we explored 
which pathways are exploited by human ovarian cancer 
cells resistant to cisplatin (IGROV1 Pt) to escape drug 
cytotoxicity. Cisplatin resistance is a multifactorial 
phenomenon, whose molecular mechanisms are still 
not completely understood. In our previous studies, 
we demonstrated that, among others, also deregulated 
metabolism might be involved in the onset of drug 
resistance revealing that cisplatin-resistant ovarian cancer 
cells (C13) underpin profound metabolic changes as 
compared with their sensitive counterpart (2008) [9, 10]. 
In particular, we observed that resistant cells increase their 
demand for glucose that is partially redirected toward the 
pentose phosphate pathway (PPP). Here we investigated 
the hypothesis that IGROV1 cisplatin-resistant cells 
might present a similarly altered phenotype that could 
be effectively targeted to restore drug sensitivity. 
Interestingly, we have found that IGROV1 Pt cells switch 
their metabolism toward the glycolytic pathway and rely 
on PPP to elude cisplatin cytotoxicity. Moreover, It has 
been demonstrated that the drug sensitivity could be 
restored by inhibiting the enzyme glucose-6-phosphate 
dehydrogenase (G6PDH), the rate-limiting step of the PPP, 
with 6-amino nicotinamide (6-AN) [10].
Given these promising data about the metabolic 
phenotype of IGROV1 PT cells, this work aimed to 
develop a strategy able to target PPP and, at the same 
time, to reduce cisplatin toxicity by proposing a new 
combination approach of 6-AN and liposomes loaded with 
cisplatin.
Cisplatin-loaded liposomes are a good strategy to 
reduce side effects and improve the antitumor efficacy of 
the drug [11, 12]. Currently, there are different platin-based 
formulations in clinical trials such as Lipoplatin, loaded 
with cisplatin [13], and Lipoxal, loaded with oxaliplatin 
[14, 15]. Most of these platin-loaded liposomes are based 
on saturated phospholipids, which yield slow rate of drug 
release with a consequent low antitumor efficacy in vitro 
but better liposome stability in vivo [16]. In fact, the lipid 
composition, and therefore the transition temperature 
of phospholipids, is a very important criterion for the 
development of a successful liposomal drug delivery 
system of anticancer drugs. The rate of cisplatin release 
can be increased by using unsaturated phospholipids 
and a reduced amount of cholesterol, thus increasing the 
fluidity and permeability of phospholipid bilayer [17]. In 
fact, in the case of OC, the liposomal formulation will 
be injected intraperitoneally and, therefore, it is relevant 
that the loaded drug is released with a favorable kinetic 
allowing the desired cytotoxic effect. On the other hand, 
such formulation might be less stable in vivo, but this 
issue can be circumvented through a polyethylene glycol 
(PEG) coating of the vesicles’ surface, an approach known 
as PEGylation and that prolongs the pharmacokinetic 
profile of liposomes [18]. Usually, the polymer is 
anchored to the phospholipid bilayers by a distearoyl 
phosphoethanolamine (DSPE) covalently coupled to 
PEG, PEG-DSPE. The so-called stealth liposomes (SLs) 
outperformed the classic naked liposomes (CL) in terms 
of circulation half-life in vivo and this technology has 
been used in clinical practice for more than 20 years [19]. 
It has been demonstrated that the hydrophobic anchor, 
interacting with the phospholipid bilayer, is extremely 
relevant to maintain the PEG chain attached to the 
surface of liposomes [20], thus avoiding interaction with 
blood proteins that promote liposome clearance [21]. 
To strengthen such interaction and consequently gain 
a further stabilization of the PEG coating we recently 
proposed a specific PEG-dendron able to carry up to four 
DSPE molecules. Such PEG-dendron-(DSPE)n derivative 
yielded liposomes with a prolonged pharmacokinetic in 
vivo, gaining a further extension of the circulation half-life 
of these coated liposomes with respect to SLs; they were 
called super-stealth liposomes (SSLs) [22].
Owing to the interesting features of SSLs, we 
here investigated the potential of such delivery system, 
prepared with unsaturated phospholipids as the main 
constituent, in overcoming OC resistance to cisplatin by 
testing in vitro a combination of liposomal cisplatin and 
6-AN.
RESULTS
Preparation and characterization of cisplatin-
loaded liposomes
Initially, the CL liposomes were prepared by 
using only S75 and cholesterol (8:2 molar ratio). The 
hydrodynamic diameters of liposomes were approximately 
between 110-140 nm with a polydispersity index (PDI) of 
0.1. This formulation showed a good encapsulation with an 
encapsulation efficiency of 18.5% ± 2.47 (0.85% cisplatin/
lipid w/w). Cisplatin release studies of such formulation 
showed a very fast release of the encapsulated drug with 
almost 50% and 80% of cisplatin released in only 5 h and 
24 h, respectively, (Figure 1A). To circumvent this issue 
about one-third of the phospholipids in the formulations 
was substituted with HSPC. These formulations presented 
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a higher cisplatin encapsulation, as shown in Table 1, and 
a mean particle size comparable to previous formulations 
while, as desired, the cisplatin release was slower with 
40-50% of the drug still entrapped in the liposomes at 24 
h (Figure 1B). Although the drug release was optimized, 
the cisplatin release itself hampered the storage of the 
liposomes in the solution owing the accumulation of free 
cisplatin that would affect, the next in vitro/in vivo studies. 
Consequently, a lyophilized liposomal formulation was 
developed and the lyophilization process was optimized 
for such liposomes, thus allowing long-term storage 
without cisplatin release.
The liposomes were lyophilized and the effect 
of two disaccharides (trehalose and sucrose) as 
cryoprotectant was evaluated. Lyophilization can alter 
the organization of liposome bilayer causing vesicle 
disruption, with changes in vesicles size and PDI, and 
drug release. In this study, the changes of vesicles size and 
the PDI were measured before and after lyophilization by 
DLS. Different molar ratios of cryoprotectant with respect 
to phospholipids were tested by adding the disaccharide 
in the solution used for the hydration of the thin lipid 
film and in the purified liposome solution after the 
elimination of free cisplatin. The values of vesicles size 
and PDI of CL before and after lyophilization, are shown 
in Table 2. Lyophilization induced a dramatic increase 
on size and PDI values of liposomes when low amounts 
of cryoprotectant were used while a good protection 
was achieved for both cryoprotectants at the ratio 1:6 
phospholipid/cryoprotectant (w/w). The lyophilization 
process did not affect the percentage of drug encapsulation 
into liposomes formulation. Similar results were obtained 
for SSL2 and SSL4.
Sucrose was more effective in preserving the 
liposomes stability also at lower amounts with respect to 
trehalose. Although the interesting cryoprotective effect 
of sucrose, this disaccharide was affecting the in vitro 
cytotoxicity investigation because it induced cells growth 
and protected cisplatin-resistant cells against the activity of 
the drug (Supplementary Figure 1). Consequently, all the 
following studies have been performed with lyophilized 
liposomes containing trehalose as cryoprotectant at the 
molar ratio of 1:6 phospholipid/cryoprotectant (w/w).
Serum stability of CL, SSL2s, and SSL4s incubated 
up to 24 h in FBS/PBS (50/50) mixture, was evaluated 
by monitoring the size of vesicles and showed no 
significant changes of size and PDI during the time for all 
formulations.
Glucose metabolism in cisplatin-resistant cells
In line with our previous data, the cisplatin 
resistant cells exhibited a glucose-dependent phenotype 
[10]. In fact, the treatment with the glycolysis inhibitor 
2-deoxyglucose (2DG) reduced cell viability of both 
cell lines and in particular that of resistant cells (-60%) 
(Figure 2A). mRNA expression of glycolysis enzymes 
was analyzed and as shown in Figure 2B, resistant cells 
presented higher mRNA levels of glycolytic enzymes 
compared to the wild type. In particular GLUT-1 mRNA 
resulted in 2.2 fold increase. The glucose transporter 
GLUT1 expression resulted up-regulated (1.33 fold) 
in resistant cells (Figure 2C). In line with these data, 
IGROV1 PT cells presented increased glucose uptake 
(Figure 2D). Together, these data showed that cisplatin-
resistant cells are more dependent on glucose when 
compared to the cisplatin-sensitive counterpart.
Glucose-6-Phosphate Dehydrogenase (G6PDH): 
Target for cisplatin-resistant cells
G6PDH is a key enzyme of the PPP activity. G6PDH 
mRNA (Figure 3A) and protein (Figure 3B) expressions 
were increased in IGROV1 PT cells when compared to 
Figure 1: Cisplatin release from different liposomal formulations. (A) Cisplatin release from CL liposomes prepared with only 
S75 and cholesterol (8:2 molar ratio). (B) Cisplatin release from CL, SSL2, and SSL4 liposomes prepared with S75:HSPC:Chol (63:25:12) 
for CL and of S75:HSPC:Chol:PEG-DSPE2 or PEG-DSPE4 (60:24:12:4) for SSL2 and SSL4, respectively. Data are the mean ± SEM of 3 
independent experiments.
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the sensitive counterpart (3.5 fold). Also, we evaluated 
the G6PDH activity, which was increased in IGROV1 PT 
cells in comparison to IGROV1 WT (Figure 3C). In order 
to confirm the specific phenotype, cells were incubated 
with a competitive G6PDH inhibitor: 6-AN [10]. As 
shown in Figure 3D, the cell viability was analyzed after 
24h treatment with 6-AN (0.5-500 μM). The IGROV1 
PT resistant cells, as compared to cisplatin-sensitive cells, 
were significantly more sensitive to 6-AN at the highest 
drug concentration. In order to verify the effects of the 
association of 6-AN with cisplatin at concentrations lower 
than its IC50 (Supplementary Table 3), isobolographic 
analysis (Figure 3E-3F) and correlated combination index 
(Supplementary Table 2) were calculated based on the 
data reported in Supplementary Table 1. In IGROV1 
WT cells, the approximate linearity of the iso-effective 
concentrations (producing 25% of cytotoxic effect) suggests 
no interaction between the two drugs (Figure 3E). In the 
IGROV1 PT, a synergism was found (Figure 3F), but at 
higher concentrations of 6-AN. These results confirmed 
that cisplatin-resistant cells present a phenotype that has 
an increased dependence on glucose, is more sensitive to 
glycolysis inhibition and overexpressed PPP when compared 
to the cisplatin-sensitive counterpart.
Cytotoxicity of liposomal cisplatin formulations
Cell viability assays of different cisplatin liposomal 
formulations (CL, SSL2, and SSL4) were carried out 
on sensitive and resistant cells. Empty liposomes did 
not show any cytotoxic effect in both cell lines at the 
concentrations used with the cisplatin loaded liposomes 
(supplementary material Supplementary Figure 2).
The effect on cell viability of cisplatin-loaded CLs, 
SSL2s, and SSL4s (0.1-5 μM cisplatin equiv.) after 24h 
treatment is shown in Figure 4. All liposomes presented 
similar concentration-dependent cytotoxic activity in both 
cell lines. These activities were also comparable to that of 
free cisplatin.
Pharmacokinetics of cisplatin-loaded liposomes
The pharmacokinetic profiles of free cisplatin and 
cisplatin-loaded CLs, SSL2s, and SSL4s were investigated 
in female Lewis rats after a single bolus injection at 3 mg/
kg cisplatin equiv. (Figure 5). The blood concentration of 
free cisplatin decreased rapidly after injection and the drug 
was not detectable after 48 h. As expected all liposomal 
formulations of cisplatin showed a prolongation in the 
pharmacokinetic profile with respect to the free drug. Both 
SSLs outperformed the CLs, in particular, SSL4s showed 
values of elimination half-life and area under the curve 
2-fold and 3-fold higher than CLs (Table 3).
Confocal microscope
Owing to the better pharmacokinetic performance 
of SSL4s, the next characterizations have taken into 
Table 2: Investigation of different amounts of cryoprotectant for liposome stabilization during lyophilization (n = 3)
Molar ratio 
Phospholipids / 
Cryoprotectant
Mean Particle Size 
(nm ± SD) PDI ± SD
Mean Particle Size 
(nm ± DS) PDI ± SD
Before lyophilisation After lyophilisation 
  Sucrose   
CL 1:2 136 ± 0.9 0.080 ± 0.009 557 ± 1.12 0.451 ± 0.052
CL 1:5 139± 0.8 0.098 ± 0.007 145 ± 1.2 0.141 ± 0.006
  Trehalose   
CL 1:2 140.9 ± 1.6 0.098 ± 0.006 657 ± 1.52 0.651 ± 0.05
CL 1:5 120.4 ± 1.2 0.082 ± 0.022 235 ± 1.1 0.21 ± 0.06
CL 1:6 132.2 ± 1.1 0.062 ± 0.011 128 ± 1.15 0.082 ± 0.022
Table 1: Encapsulation efficiency and cisplatin loading of liposomal formulations (n = 3)
Formulation cisplatin encapsulation efficiency (%) cisplatin/lipid (% w/w)
cisplatin/CL 25.1 ± 0.71 1.14 ± 0.03
cisplatin/SSL2 25.7 ± 0.94 1.19 ± 0.04
cisplatin/SSL4 25.9 ± 0.86 1.21 ± 0.04
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consideration only such formulation. Time-lapse/live 
confocal laser scanning microscope images (Figure 6) 
showed cellular internalization of fluorescein-labelled 
0.5 μM cisplatin/SSL4s, following 6 h of treatment. 
The cell membrane of both sensitive and resistant cell 
lines was labeled with a CellMaskTM Orange Plasma 
membrane Stains. As shown in Figure 6, cisplatin/SSL4 
interacted with cells and the fluorescence intensity was 
higher in wild-type with respect to resistant cell line. The 
fluorescence of fluorescein was co-localized with the 
membrane suggesting the fusion of the liposomes with 
the cells and the consequent release of cisplatin in the 
cytoplasm.
Combination activity of cisplatin/SSL4 with 
6-AN
To evaluate the effect of G6PDH inhibition by 
the 6-AN and cytotoxic activity of cisplatin, in free 
or liposomal form, the two compounds were tested 
in IGROV1 WT and IGROV1 PT. The concentration 
of cisplatin equiv. was fixed at 0.5 μM, lower than 
cisplatin IC50 (reported in Supplementary Table 3), 
while increasing doses of 6-AN (1-10 μM) were tested 
(Figure 7). In IGROV1 WT the cell cytotoxicity 
was caused prevalently by cisplatin (free or SSL4). 
On the contrary, in resistant cells, the effect of the 
combination of 6-AN 1 μM with 0.5 μM cisplatin /SSL4 
Figure 2: IGROV1 PT cells present an increased dependency on glucose. (A) Cell viability after 24 hours of treatment with a 
glucose-free medium added with 0.5 and 1mM 2-DG. Data are expressed as the percentage of cell number compared to control. (B) Key 
genes mRNA levels involved in the glycolytic flux measured by qRT-PCR. All genes were normalized to calnexin as endogenous control 
and data are expressed as a ratio of IGROV1 PT to IGROV1 WT. (C) GLUT1 protein expression measured by western blotting. GLUT1 
was normalized to calnexin. (D) Glucose uptake measured after incubation with the glucose analog 6-NBDG. Data are normalized to 
cisplatin-sensitive cells. Data are the mean ± SEM of at least 3-5 independent cultures. ***p<0.001, *p<0.05; IGROV1 PT vs IGROV1 WT. 
§§§p<0.001; treatment vs control.
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Figure 3: Inhibition of G6PDH, rate-limiting step of PPP, mainly affect cisplatin-resistant cells. (A-C) G6PDH mRNA 
levels (A), protein expression (B) and enzymatic activity (C) were quantified respectively by qRT-PCR, western blotting and the enzymatic 
assay kit of Cayman Chemical Company. (D) Effect of 6AN (0.5-500 μM) on IGROV1 cell viability after 24+48 h of treatment. (E-F) 
Isobologram of cisplatin-sensitive (E) and cisplatin-resistant (F) cells showing the effect of 6-AN in association with cisplatin treatment. 
Data are expressed as a percentage of control. The graph was obtained using iso-effective drug concentrations causing 25% of the cytotoxic 
effect. Data are the mean ± SEM of at least 3-5 independent cultures. ***p<0.001, **p<0.01, *p<0.05; IGROV1 PT vs IGROV1 WT. 
+++p<0.001; treatment vs control.
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was more effective with respect to free cisplatin. These 
data demonstrated that the combination of cisplatin/
SSL4 with inhibition of the PPP enzyme G6PDH can 
remarkably increase the cytotoxic activity of cisplatin 
and can overcome cisplatin cancer resistance. In Table 4 
the combination index values calculated by the Chou & 
Talalay [23] are reported. The same combination was 
also tested in 2008 and C13 ovarian cancer cell lines 
confirming the efficacy of the treatment as reported in 
Supplementary Figure 5.
DISCUSSION
Chemotherapy remains the principal therapeutic 
approach in cancer treatment. Despite recent successes, 
resistance and relapse are still major obstacles [7]. Hence, 
novel pharmacological strategies addressing such issues 
are urgently needed.
Nanosized carriers have the potential to improve 
biopharmaceutical features, pharmacokinetic properties 
and the therapeutic effectiveness of anticancer drugs [24]. 
Figure 4: Cisplatin/liposomes delivery does not change cisplatin effectiveness in both IGROV1 cell lines. (A-B) Effect 
of cisplatin alone or delivered by 3 different liposomal formulations (lyophilized with trehalose) in cisplatin-sensitive (A) and cisplatin-
resistant (B) cells. The effect was measured after 24+48 h of treatments by SRB test. Data are the mean ± SEM of at least 3-4 independent 
cultures. §§§p<0.001; treatment vs control. Data are expressed as a percentage of control.
Figure 5: Liposomal formulations of cisplatin showed prolonged pharmacokinetic profiles. Pharmacokinetic profiles of 
free cisplatin and cisplatin -loaded liposomes (CLs, SSL2s. and SSL4s) in female Lewis rats (n=3 per group) after i.v. injection via tail vein 
of 3 mg/kg cisplatin equiv. Data are the mean ± SEM.
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In the light of this view, we here report that a cisplatin 
liposomal formulation, obtained by a new approach of 
PEGylation, in combination with the PPP inhibitor 6-AN 
might represent a new therapy approach against cisplatin-
resistant cancers.
Cisplatin is one of the most used chemotherapy 
drugs for the treatment of OC, but unfortunately, drug 
resistance is readily seen in patients during the therapeutic 
treatment [25]. Furthermore, the clinical use of cisplatin is 
limited by its severe side effects, including nephrotoxicity 
and ototoxicity. Dose-related and cumulative renal failure 
is the major dose-limiting toxicity of cisplatin. A single 
dose of 50 mg/m2 induced renal toxicity in 28% to 36% 
and ototoxicity in up to 31% of patients treated. The 
toxicity, also associated with drug resistance, created the 
limits in clinical management. Strategies for modifying 
cisplatin uptake into cancer cells and the pharmacokinetic 
profile may be useful for reducing toxicity and resistance 
while increasing therapeutic efficacy [25].
Liposomes are well-known drug delivery systems, 
already clinically approved, exploited for improving 
pharmacokinetics, anticancer efficacy, and reducing 
systemic toxicity of many anticancer drugs. The 
PEGylated form of liposomes, called stealth liposomes 
(SLs), represents a smart approach to escape macrophage 
uptake and gain a prolonged circulation time in blood. 
Recently, we proposed a new type of PEGylated 
liposomes in which the hydrophobic anchor, which keeps 
the polymer attached to the liposome surface, was greatly 
increased by linking up to four phospholipid moieties to a 
single PEG chain instead of a single phospholipid (PEG-
DSPE) as is commonly used in SLs [22]. These new 
PEG derivatives, namely PEG-DSPE2 and PEG-DSPE4, 
offered an increased stability of the PEG layer around 
the liposomes, termed SSLs. In the development of new 
liposomal formulation, it is of fundamental relevance 
the physicochemical properties of the lipid bilayer that 
influence the processes of drug encapsulation and release. 
In particular for cisplatin, phospholipids with a higher 
temperature of transitions (Tm), such as HSPC, showed a 
better retention of the entrapped drug [26]. Taking in mind 
that our scope was to develop a cisplatin delivery system 
for the treatment of OC through intraperitoneal injections, 
we focused on SSLs that can release the entrapped drug 
within 2-3 days. The preliminary investigation based on 
liposomes constituted of the unsaturated S75 phospholipid 
and cholesterol was unsatisfactory because cisplatin was 
released completely within 24 h. The unsaturated S75 
phospholipid increased the fluidity and permeability of 
the liposome bilayer with respect to saturated lipids. To 
balance the increased fluidity and improve the stability of 
the vesicles, one-third of the S75 amount was substituted 
with the saturated HSPC phospholipid achieving the 
desired release profile. Nevertheless, such cisplatin release 
required the development of a lyophilized liposome 
formulation to avoid drug leakage during storage, which 
would have hampered the cytotoxicity testing and the 
potential future exploitation. Trehalose and sucrose were 
investigated as a cryoprotectant to preserve liposome size 
and drug encapsulation. Although both agents worked well 
in the preservation of vesicles morphology, sucrose had the 
disadvantage to reduce cisplatin activity, especially in the 
resistant cell line (Supplementary Figure 1), thus further 
confirming a role of the metabolic pathway in cisplatin 
resistance. Differently, the cells could not metabolize 
trehalose; therefore, it was selected as the cryoprotectant 
for all the tested liposomal formulations. The stabilization 
offered by the PEG layer on the liposome surface was 
investigated by a pharmacokinetic study in rats. The 
profile of cisplatin concentration in plasma for SSLs, 
and in particular for SSL4, surpasses that of conventional 
liposomes by showing a clear half-life prolongation and an 
increase in the AUC values (Table 3).
The second goal of this work was to target specific 
pathways correlated to cisplatin resistance in order to 
increase drug efficacy. Cisplatin resistance is generally 
considered a multi-factorial phenomenon causing, among 
others, changes in drug transport and accumulation, 
increases of DNA repair and detoxification systems 
as well evasion from apoptotic cell death [27]. These 
alterations might also play a role in the observed different 
internalization of the cisplatin/SSL4s between wild-
type and resistant cell lines (Figure 6). In the last years, 
emerging evidence supported the involvement of cell 
metabolism reprogramming in resistance to cisplatin [28].
G6PDH is the first and rate-limited enzyme of the 
PPP, which is expressed in almost all cells. Recent studies 
demonstrated that G6PDH was involved in cell growth 
Table 3: Elimination half-life (T½ β) and area under the curve (AUC) of free cisplatin and liposomal formulations of 
cisplatin in Lewis rats (n=3) after the i.v. injection of 3 mg/kg of cisplatin equiv
Formulation T½ β (h) AUC (μg/ml·h)
cisplatin 52.14 250.19
cisplatin /CL 62.26 719.36
cisplatin /SSL2 110.72 1411.57
cisplatin /SSL4 179.81 2334.64
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modulation and carcinogenesis. In previous studies we 
demonstrated that the overexpression and increased 
enzymatic activity of G6PDH were correlated to ovarian 
cisplatin-resistant phenotype cells [10], suggesting that 
up-regulation of G6PDH activity could be a target to 
counteract cisplatin resistance. In fact, the combined 
treatment with the G6PDH inhibitors (6-AN or DHEA) 
and cisplatin, exhibited a selective additive effect on 
cisplatin-resistant cells [10].
Present data support that SSLs of cisplatin can 
become a strategy to counteract cisplatin resistance 
especially in combination with 6-AN. A combination 
of cisplatin/SSL4 with the targeted metabolic inhibition 
of PPP showed a better efficacy than the cisplatin alone 
Figura 6: Time-lapse/live confocal laser scanning microscope images of IGROV1 WT and IGROV1 PT incubated with 
cisplatin/SSL4. Cells were incubated with fluorescein-labeled cisplatin/SSL4s 0.5 μM for 6 h. To stain plasma membrane in live cells 
CellMaskTM Orange Plasma membrane stain was used. Green: liposome, red: cell membrane. Scale bar is 10 μm.
Figure 7: Co-treatment of 6AN and cisplatin/SSL4 increases drug activity in IGROV1 PT cells. (A-B) Effect of 6AN and 
cisplatin/SSL4 association in cisplatin-sensitive (A) and cisplatin-resistant (B) cells. The effect was measured after 24+48 h of treatments 
by SRB test. Data are the mean ± SEM of at least 3-4 independent cultures. ***p<0.001, **p<0.01, *p<0.05; association vs 6AN. §§p<0.001, 
§§p<0.01; association vs cisplatin. Data are expressed as a percentage of control.
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(Figure 7). The fact that the cisplatin/SSL4 had a similar or 
better cytotoxic effect than cisplatin when both were used 
in combination with 6-AN, is a promising result in view of 
the prolonged effect that can be achieved with a liposomal 
formulation of cisplatin in vivo and the concomitant 
reduced toxic effect of the drug.
MATERIALS AND METHODS
Materials
Non-hydrogenated soy phosphatidylcholine (S75) 
was a kind gift of Lipoid (Ludwigshafen, DE, Germany); 
hydrogenated soy phosphatidylcholine (HSPC) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
(DSPE) were purchased from NOF Corporation (Tokyo, 
JP). Cisplatin, 6-aminonicotinamide (6-AN), triton 
X-100, trehalose, sucrose, o-phenylenediamine (OPDA), 
cholesterol (Chol), trypan blue, Sulforhodamine B and all 
solvents and reagents were obtained from Sigma-Aldrich 
Co. (Milan, IT). N-(Fluorescein-5-thiocarbamoyl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine 
triethylammonium salt (fluorescein-DHPE) was 
purchased by Invitrogen (USA). PEG5k-βGlu-(DSPE)2 
(PEG-(DSPE)2) and PEG5k-βGlu(βGlu)2-(DSPE)4 (PEG-
(DSPE)4) were prepared as described previously [22].
Cell lines
Human ovarian carcinoma cells
IGROV1 wild-type and the cisplatin-resistant 
subclone (kind gift of Dr. Giuseppe Toffoli, CRO Aviano 
National Cancer Institute, Italy) were grown in a cisplatin-
free in Roswell Park Memorial Institute medium (RPMI 
1640) supplemented with 10% fetal bovine serum (FBS), 
4 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin, in humidified condition at 5% CO2 and 
37°C. Cisplatin-resistant subclones (respectively IGROV1 
PT; Supplementary Figure 3) were generated in Toffoli’s 
lab according to previously standardized protocols. 
All reagents for cell culture were from Cambrex-Lonza 
(Basel, Switzerland) and FBS from Gibco, Invitrogen 
(Carlsbad, CA, USA). The growth kinetics are shown in 
Supplementary Figure 4.
Preparation of liposomes
All liposomes were prepared by the thin layer 
evaporation method. Classic liposomes (CLs) were 
prepared with S75, HSPC, and cholesterol in a molar 
ratio of 63:25:12. The molar ratio composition of super 
stealth liposomes, SSL2s and SSL4s, were 60:24:12:4 
of S75:HSPC:Chol:PEG-DSPE2 or PEG-DSPE4, 
respectively. When required, fluorescent-labeled 
liposomes were prepared by co-dissolving fluorescein-
DHPE (0.6% molar with respect to S75) with the 
lipids. The lipid mixture, composed of about 24.5 mg 
of phospholipids equiv. divided between the different 
species according to the ratios above reported, and 2.16 
mg of Chol were dissolved in 0.2 ml of chloroform. A 
thin lipid film was obtained by evaporation of the organic 
solvent under a stream of nitrogen (N2) and further 
vacuum-dried for 24 h to remove any residual organic 
solvent. The film was hydrated with 1 ml of cisplatin 
solution at 1 mg/ml in PBS and the resultant liposomal 
suspension was incubated at 70° C for 1 h with gentle 
mixing. Small unilamellar vesicles (SUV) were obtained 
by serial extrusion cycles through polycarbonate filters 
with a pore size ranging from 400 to 100 nm at 70°C 
using a syringe extruder Liposofast (Avestin Inc., 
CA). The separation of the no-encapsulated drug from 
the liposomes was achieved by ultrafiltration with an 
Amicon Ultra centrifugal tube cut-off 10 kDa (Millipore). 
When needed trehalose as cryoprotectant was added 
to the hydration solution at different concentrations 
(cryoprotectant: phospholipid 2:1, 5:1 or 10:1 mass 
ratio) and to the purification solution (cryoprotectant: 
phospholipid 6:1, mass ratio). Then the liposomal 
formulations were frozen at -80°C for 24 h and, finally, 
lyophilized. The liposomes were reconstituted to the 
initial volume by the addition of milliQ water.
Table 4: Combination index of cisplatin/SSL4 and 6-AN in wild-type and resistant cell lines
Conc. cisplatin/SSL4 (μM) Conc. 6AN (μM)
IGROV1 WT IGROV1 PT 
Effect CI Effect CI
0.1 1 0.8845 7.371 0.873 0.956
0.1 5 0.7382 0.316 0.811 1.176
0.1 10 0.676 0.211 0.327 0.552
0.5 1 0.6397 0.852 0,647 0.661
0.5 5 0.608 0.717 0.661 1.147
0.5 10 0.535 0.487 0.362 0.681
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Characterization of cisplatin-loaded liposomes
Size characterization
The average particle size and the polydispersity 
index (PDI) of CLs, SSL2s, and SSL4s were measured 
on a dynamic light scattering (DLS) instrument Zetasizer 
Nano ZS (Malvern, UK). Phospholipid concentrations in 
liposome solutions were measured by Stewart assay, based 
on a colorimetric determination of inorganic phosphate.
Drug loading
Cisplatin concentration was determined with a 
spectrometric method developed by Basotra et al [29]. 
From a solution of liposomal cisplatin aliquots of 20 
μL were withdrawn and placed in 1 mL glass test tubes. 
Then 100 μL of OPDA solution at 1.4 mg/mL and 200 
μL of phosphate buffer 5 mM pH 6.8 were added to each 
solution and heated at 100°C for 10 min in order to get 
the formation of a light green color. The solutions were 
cooled to room temperature, and brought to 1mL with 
DMF. The UV absorption at 706 nm was measured by a 
UV-Vis spectrophotometer.
A solution of cisplatin in 5 mM phosphate buffer pH 
6.8 at a concentration of 10 μg/mL was used to prepare a 
calibration curve.
Serum stability
An aliquot of about 20 mg in phospholipid equiv. of 
each cisplatin-loaded liposomes was resuspended in 2 ml 
of FBS/PBS (50/50) mixture and independently incubated 
for 24 hours at 37°C. Samples were analyzed by DLS for 
24 h.
Drug release
1 mL of a liposome suspension was loaded into a 
dialysis tubes (Float-A-Lyzer G2, 100,000 MWCO) and 
placed in a becker filled with 500 mL of PBS and kept 
under stirring. The system was thermostated at 37°C. 
Aliquots (20 μL) were withdrawn from the dialysis tube 
at different time points to measure the content of cisplatin 
as above reported.
Cell viability assays
Trypan blue exclusion assay
1x105 cells were plated on 12-well plates and, 
following overnight incubation, were exposed to a 
glucose-free medium added with 1mM 2-deoxyglucose 
(2-DG) for 24 hours. After treatment, cells were washed, 
detached with 0.25% trypsin-0.2% EDTA and suspended 
in trypan blue at 1:1 ratio in medium solution [30]. Cells 
were counted using a chamber Burker hemocytometer.
Sulforhodamine B (SRB) test
4x103 cells were plated on 96-well plates and, 
following overnight incubation, were exposed to different 
treatments according to experimental protocols. After 
treatments cells were fixed with trichloroacetic acid and 
stained with SRB as previously described [10]. The bound 
SRB was therefore dissolved by adding 10 mM TRIS and 
the absorbance was measured at 570 nm using a Victor3X 
multilabel plate counter (Wallac Instruments, Turku, 
Finland).
Immunoblot assay
1.5x106 cells (IGROV1) were plated in 100 mm 
cell culture dish and allowed to attach overnight. After 
48 hours, cells were washed and lysed with ice-cold lysis 
buffer (TRIS 25 mM pH 7,4; NaCl 150 mM; IGEPAL 
1%; sodium deoxycholate 1%; SDS 0,1%; EDTA 1 mM) 
supplemented with the protease inhibitor cocktails (Roche 
Molecular Biochemicals, Mannheim, Germany). Cell 
lysates were then centrifuged at 14000 rpm for 15 minutes 
at 4°C and the supernatant protein content was determined 
by Lowry procedure (Bio-rad DC Protein Assay, MA, 
USA). Equal amounts of protein (40 μg) were loaded 
on a 10% polyacrylamide gel and electrophoretically 
separated in running buffer. After electrophoresis, the 
proteins were blotted onto a Hybond-P PVDF membrane 
(Amersham Biosciences, Buckinghamshire, UK) and 
non-specific binding sites were blocked with a 10% skim 
milk solution. The membrane was therefore exposed 
to the elected primary antibody: anti-GLUT1 (1:2000; 
AbCam, Cambridge, UK) or anti-G6PDH (1:500; 
Santa Cruz Biotechnology, Inc., Europe) and, following 
overnight incubation, was washed and exposed to the 
HRP-conjugated anti-rabbit secondary antibody (1:3500; 
PerkinElmer, MA, USA). The signal was visualized 
with an enhanced chemoluminescent kit (Amersham 
Biosciences) according to the manufacturer’s instructions 
and analyzed by Molecular Imager VersaDoc MP 4000 
(Bio-Rad, Hercules, CA, USA). GLUT1 and G6PDH 
were normalized to calnexin (1:2000; Rabbit, Santa Cruz 
Biotechnology). The integrated intensities of GLUT1 and 
G6PDH were normalized to calnexin.
Quantitative real-time PCR
Total mRNA was extracted as per manufacturer’s 
instructions using a Direct-zol™ RNA MiniPrep kit 
(Zymo Research, Irvine, CA, USA) and measured with 
a NanoDrop 2000 (Thermo Fischer Scientific Inc., 
Waltham, MA, USA). The relative expression of each 
gene was determined by quantitative real-time PCR 
(Eco™ Illumina, Real-Time PCR system, San Diego, 
CA, USA) using One Step SYBR PrimeScript RT-PCR 
Kit (Takara Bio, Inc., Otsu, Shiga, Japan) and the primers 
designed as follow: G6PDH: F aagaacgtgaagctccctga R 
aatataggggatgggcttgg; GLUT1: F atgggcttctcgaaactggg 
R ccgcagtacacaccgatgat; PFKM: F gccatcagcctttgacaga 
R ctccaaaagtcgcatcactg; PGK1: F cagctgctgggtctgtcat, 
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R gctggctcggctttaacc; LDHA: F tggcagccttttccttagaa R 
cgcttccaataacacggttt. Melt-curve analysis was used to 
confirm the specificity of amplification and absence of 
primer dimers. All genes were normalized to calnexin 
designed as follow: F: gaagggaagtggttgctgtg R: 
gatgaaggaggagcagtggt. Expression levels of the indicated 
genes were calculated with the ΔΔCq method [31] using 
the dedicated Eco™ Software v4.0.7.0. Wild-type cells 
were used as reference sample. Briefly, this method 
normalizes the expression of the target genes relative to 
a single reference gene; thereafter the obtained relative 
expressions are normalized to a reference sample. The 
exact calculations are adapted from Livak, et al. as follow: 
∆Cq = Cq(Target Assay) - Cq(Reference Assay); ∆∆Cq = ∆Cq(Test Sample) 
- ∆Cq(Reference Sample); RQ = 2
-∆∆Cq.
Glucose uptake
IGROV1 glucose uptake was measured as 
previously described [10]. Briefly, 5x103 cells (IGROV1) 
were plated in 96-well plate and allowed to attach 
overnight. After 24 hours, cells were stained for 5 minutes 
with the glucose analog 6-NBDG (Invitrogen, Paisley, 
UK) and their fluorescence (λex: 465 nm, λem: 540 nm) was 
measured by Victor3X multilabel plate counter (Wallac 
Instruments, Turku, Finland).
G6PDH activity
1.5x106 cells (IGROV1) were plated in 100 mm 
cell culture dish and allowed to attach overnight. After 48 
hours, cell samples were prepared as previously described 
[10]. The G6PDH activity was assayed on cell supernatant 
as per manufacturer’s instructions using the Glucose-6-
Phosphate Dehydrogenase Activity Assay Kit (Cayman 
Chemical Company, MI, USA). The fluorescence 
intensity (λex/em=540/585) was measured using a 
Victor3X multilabel plate counter (Wallac Instruments, 
Turku, Finland). The G6PDH activity (nmol/min/ml) was 
calculated as per manufacturer’s instructions.
Live-cells confocal microscopy
25x104 cells (IGROV1) were grown in 4-wells 
glass-bottom culture chambers (Sarstedt AG & Co, 
Nümbrecht, Germany) and, after 24 hours, were 
labeled with LysoTracker® Deep Red (Molecular 
Probes, Invitrogen) or CellMaskTM Orange Plasma 
membrane Stains (Molecular Probes, Invitrogen) as 
per manufacturer’s instructions. After staining, cells 
were washed, loaded with the fluorescent cisplatin/
SSL4 0.5 μM and the images were periodically acquired 
for 24 hours using a time-lapse confocal microscope 
(Zeiss LSM 800, 40X magnification). A volumetric 
reconstruction was then obtained using the software 
ZEN 2.1 (blue edition).
Statistical analyses
All data were analyzed with GraphPad software 
and are expressed as mean ± SEM. Standard ANOVA 
procedures were performed for all the cell viability assays 
except for the SRB tests after cisplatin and 6-AN treatments 
that were analyzed with unpaired Student’s t-tests. One 
sample t-tests were used to analyze results expressed as 
a ratio of control (qRT-PCR and glucose uptake), while 
unpaired Student’s t-tests were performed for all the other 
results. Significance was considered at p< 0.05.
Isobolographic analysis
The isobolographic analysis was used to determine 
the effect of cisplatin and 6-AN co-treatment. Isoboles are 
defined as iso-effect curves. that show drug concentrations 
resulting in equal effect [32, 33]. From iso-effective 
curves it is possible to verify the presence of simple 
additivity, supra-additivity (synergism) or infra-additivity 
(antagonism).
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Ministry of Health (938/2016-PR), and animals were 
handled in compliance with national (Italian) Legislative 
Decree 116/92 guidelines and with the “Guide for the Care 
and Use of Laboratory Animals” by the National Research 
Council of the National Academies.
Pharmacokinetic study
FemaleLewis rats (weight 210-250 g) were 
purchased from Charles River Labs and housed in a 
temperature and humidity controlled room under a 
constant 12-hour light/dark cycle. Animals had free access 
to water and food ad libitum. Animals were randomly 
divided into four groups of three units each. Free and 
liposomal cisplatin, in CL, SSL2, and SSL4, were injected 
as a single bolus via tail vein at the concentration of 3 
mg/kg cisplatin equiv. Blood samples (100-150 μL) were 
withdrawn by the tail-tip cut method at predetermined 
time-points and placed into heparinized Eppendorf test 
tubes. Plasma samples were centrifuged at 1000g × 15’ 
to eliminate the red blood cells. The supernatant plasma 
(50 μL) were stored at -80°C until the determination of 
cisplatin by atomic absorption spectroscopy (AAS) on a 
Varian AA240Z, equipped with a sample dispenser and a 
graphite tube atomizer, GTA120. Cisplatin concentration 
in serum samples was measured against a standard curve 
obtained with a cisplatin standard solution. Each sample 
was mineralized using a solution of concentrated nitric 
acid and hydrogen peroxide (34.5-36.5%) in 1:4 (v:v). The 
mineralization process comprised four stages: a drying 
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stage consisting of 3 steps at temperature of 85, 95 and 
120°C respectively, an ashing stage at 1000°C in 3 steps 
of 5.0, 1.0 and 2.0 s, respectively, an atomization stage 
at 2700°C in 3 steps of 0.9, 2.0 and 2.0 s and a stage of 
burning-clean with cooling down at 50°C.
The instrument was operated at a wavelength of 
265.9 nm with a slit band of 0.2 nm. Each sample was 
analyzed in duplicate and the absorbance values were 
averaged.
The pharmacokinetic data elaboration was 
performed by PkSolver software by applying a 
bicompartmental model [34].
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